Skip to main
XGN

Exagen Inc (XGN) Stock Forecast & Price Target

Exagen Inc (XGN) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Exagen is well-positioned for growth and success due to its strong financials, strategic focus on a targeted market of rheumatologists, and continued expansion of its product portfolio. With a projected revenue growth of 5-10% Y/Y and plans for a new test launch every year, Exagen's positive outlook is further cemented by its development in lupus nephritis testing and biopharma services, strong sales rep traction, and emphasis on becoming a value-added partner to rheumatologists. Its current financials, including its low multiple of 1.3x projected 2026 revenue and its goal of achieving positive adjusted EBITDA in Q4'27, make it a promising investment opportunity.

Bears say

Exagen is experiencing headwinds in its average selling price (ASP) and gross margins, leading to a decline in their adjusted EBITDA. Additionally, their projected revenue and cash flow breakeven have been pushed back, raising concerns about their long-term financial sustainability. The company also faces stiff competition from established players in the medical testing industry, which may threaten their market share and growth potential.

Exagen Inc (XGN) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exagen Inc (XGN) Forecast

Analysts have given Exagen Inc (XGN) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Exagen Inc (XGN) has a Strong Buy consensus rating as of May 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exagen Inc (XGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.